A new $200m SPAC just listed on the NYSE. What industries is Kensington Capital really targeting?
Kensington Capital Acquisition Corp. VI prices a $200M SPAC IPO targeting automotive, aerospace and AI sectors. Discover what it signals for the SPAC market.
How Nebius Group’s 1.2 GW Missouri AI factory could reshape the United States AI cloud market
Nebius Group wins approval for a 1.2 GW AI factory in Missouri, signaling a major expansion in artificial intelligence infrastructure. Discover what it means for cloud computing.
SITE Centers (NYSE: SITC) sells 3030 North Broadway for $50.1m as Chicago urban retail exit signals deeper portfolio reset
SITE Centers (SITC) sells Chicago's 3030 North Broadway for $50.1M, far below its 2017 purchase price, as the REIT doubles down on strip malls. Read what this means for investors.
Can Lululemon Athletica Inc. (NASDAQ: LULU) regain product leadership with sweat-hiding ShowZero technology?
Lululemon unveils sweat-hiding fabric to stand out in activewear. Discover what this means for growth, margins, and competitors. Read more.
CONEXPO 2026 : HD Construction Equipment launches autonomous excavator lineup in U.S. debut
HD Hyundai unveils AI-powered excavators and autonomous construction tech at CONEXPO 2026. Discover how this could reshape competition in North America.
BlackRock, Inc. completes $3.25bn Naturgy exit amid European energy transition capital realignment
BlackRock exits its $3.25B Naturgy stake. Discover what this means for European utilities, capital flows, and long-term energy strategy.
Can Bridger Aerospace turn a $18.6m Alaska deal into year round revenue stability?
Bridger Aerospace (NASDAQ: BAER) secures a $18.6M Alaska contract. Discover what it means for revenue stability, utilization, and investor outlook.
Is Pinterest, Inc. (NYSE: PINS) undervalued? Elliott Investment Management’s $1bn move sparks debate
Pinterest secures $1B from Elliott Investment Management and launches a $3.5B buyback. Discover what this means for PINS stock and digital advertising.
Pfizer-backed Priovant wins FDA priority review for brepocitinib in dermatomyositis
FDA grants priority review to Priovant's brepocitinib NDA for dermatomyositis with a Q3 2026 PDUFA date. Read what this means for Roivant, Pfizer, and the autoimmune market.
Will the United States lose measles elimination status as CDC calls for urgent vaccination?
CDC acting director urges urgent measles vaccination as U.S. cases surge. Discover what this means for public health policy and elimination status.